Hematology/Oncology
Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS. Receptor discordance between primary tumors[...]
Misic A, Ghanem G, Sadeghi S, Carroll M. Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology. Thromb J.[...]
Bruyat D, Girard N, Heudel P, Penel N, Le Deley MC, Diallo I, Boher JM, Zemmour C, Chanez B, Madroszyk A, Gravis G, Billon E,[...]
Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi:[...]
Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]
Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.
Mouabbi JA, Lipsyc-Sharf MD, Yan F. Practical approach to MRD testing in breast cancer: Q&A. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):11-15. PMID: 42283709.
Wander SA, Weipert CM, Cabel L, Liao J, Zhang N, Safonov A, Bardia A, Razavi P. Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6[...]
Aggarwal H, Gupta N, Sengupta A, Sarkar A, Mylavarapu S, Pires IS, Saha T, Sarkar B, Kulkarni A, Mahajan VS, Goyal L, Bardia A, Fahrner[...]
Keramida K, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Dent S, Drakaki A, Fuster JJ, Mamas MA, Okwuosa T, Scarfo L, Van Der Meer[...]